- Home
- MCD vs LLY Comparison
MCD vs LLY Comparison
Compare MCD & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCD | LLY |
|---|---|---|
| Founded | 1940 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6B | 979.6B |
| IPO Year | 1997 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MCD | LLY |
|---|---|---|
| Price | $266.93 | $1,190.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 19 |
| Target Price | $344.17 | ★ $1,218.84 |
| AVG Volume (30 Days) | ★ 4.1M | 2.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.56% | 0.81% |
| EPS Growth | 4.92 | ★ 95.99 |
| EPS | 6.10 | ★ 16.19 |
| Revenue | $26,885,000,000.00 | ★ $65,179,000,000.00 |
| Revenue This Year | $7.65 | $27.15 |
| Revenue Next Year | $6.00 | $16.04 |
| P/E Ratio | ★ $43.95 | $76.19 |
| Revenue Growth | 3.72 | ★ 44.70 |
| 52 Week Low | $260.96 | $712.05 |
| 52 Week High | $341.75 | $1,292.65 |
Technical Indicators
Market Signals| Indicator | MCD | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 49.60 |
| Support Level | $263.73 | $1,148.95 |
| Resistance Level | $278.54 | $1,240.73 |
| Average True Range (ATR) | 4.43 | 36.35 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 18.94 | 31.11 |
Price Performance
Historical ComparisonAbout MCD McDonald's Corporation
McDonald's is the world's largest restaurant brand, with nearly $139 billion in systemwide sales across more than 45,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 62%), with the remainder stemming from company-operated restaurants across three segments: the United States (39% of systemwide sales), international operated markets (35%), and international developmental/licensed markets (26%).
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.